Abstract
Although the inhibition of cholesteryl ester transfer protein (CETP) was met with great hope as a potential mechanism for treating dyslipidemia, recent data from the ILLUMINATE trial (Journal Watch Cardiology Nov 5 2007) demonstrating increased mortality in patients receiving the CETP inhibitor torcetrapib have raised concerns about the viability of this approach. In particular, blood pressure elevation associated with torcetrapib was thought to contribute to its toxicity. To explore whether BP …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
